Login / Signup

Multivariate genome-wide association meta-analysis of over 1 million subjects identifies loci underlying multiple substance use disorders.

Alexander S HatoumSarah M C ColbertEmma C JohnsonSpencer B HuggettJoseph D DeakGita PathakMariela V JenningsSarah E PaulNicole R KarcherIsabella HansenDavid A A BarangerAlexis EdwardsAndrew Grotzingernull nullElliot M Tucker-DrobHenry R KranzlerLea K DavisSandra Sanchez-RoigeRenato PolimantiJoel GelernterHoward J EdenbergRyan BogdanArpana Agrawal
Published in: Nature mental health (2023)
Genetic liability to substance use disorders can be parsed into loci that confer general or substance-specific addiction risk. We report a multivariate genome-wide association meta-analysis that disaggregates general and substance-specific loci for published summary statistics of problematic alcohol use, problematic tobacco use, cannabis use disorder, and opioid use disorder in a sample of 1,025,550 individuals of European descent and 92,630 individuals of African descent. Nineteen independent SNPs were genome-wide significant ( P < 5e-8) for the general addiction risk factor ( addiction-rf ), which showed high polygenicity. Across ancestries, PDE4B was significant (among other genes), suggesting dopamine regulation as a cross-substance vulnerability. An addiction-rf polygenic risk score was associated with substance use disorders, psychopathologies, somatic conditions, and environments associated with the onset of addictions. Substance-specific loci (9 for alcohol, 32 for tobacco, 5 for cannabis, 1 for opioids) included metabolic and receptor genes. These findings provide insight into genetic risk loci for substance use disorders that could be leveraged as treatment targets.
Keyphrases
  • genome wide
  • genome wide association
  • dna methylation
  • systematic review
  • copy number
  • meta analyses
  • risk factors
  • chronic pain
  • gene expression
  • pain management
  • replacement therapy